Arvinas will participate in a June 3 fireside chat at the Jefferies Global Healthcare Conference, discussing its protein degradation therapies.
Quiver AI Summary
Arvinas, Inc. announced its participation in a fireside chat at the Jefferies Global Healthcare Conference scheduled for June 3, 2026. The company, which focuses on targeted protein degradation to develop innovative therapies for severe diseases, highlighted its achievements, including the FDA approval of VEPPANU™ for specific breast cancer patients, in collaboration with Pfizer. Additionally, Arvinas is advancing several investigational drugs aimed at treating various conditions, such as neurodegenerative disorders and specific types of cancer. The webcast of the presentation will be accessible on their website.
Potential Positives
- Arvinas will participate in the prestigious Jefferies Global Healthcare Conference, which highlights the company's visibility and engagement within the healthcare investment community.
- The company successfully developed VEPPANU™, the first FDA-approved PROTAC for certain advanced breast cancers, establishing Arvinas as a pioneer in the protein degradation therapy space.
- Arvinas is advancing multiple investigational drugs through clinical development, indicating a strong pipeline and commitment to addressing various serious health conditions.
- The partnership with Pfizer Inc. and the transaction with Rigel Pharmaceuticals for exclusive global rights to VEPPANU demonstrates collaboration with major industry players and potential for increased revenue streams.
Potential Negatives
- The press release does not provide any detailed updates on ongoing clinical trials or research developments, which may raise concerns about the company's progress and transparency.
- The closing of the transaction with Rigel Pharmaceuticals for VEPPANU is contingent on receiving various consents or approvals, indicating potential regulatory hurdles that may affect the timeline of the product's availability.
- Despite having a FDA-approved product, the press release focuses heavily on the company's ongoing programs without highlighting commercial success or market adoption, which could suggest challenges in monetizing their innovations.
FAQ
What is Arvinas, Inc. known for?
Arvinas, Inc. is a clinical-stage biotechnology company focusing on targeted protein degradation therapies to treat serious diseases.
When will Arvinas participate in the Jefferies Global Healthcare Conference?
Arvinas will participate in the Jefferies Global Healthcare Conference on Wednesday, June 3, at 9:55 a.m. ET.
How can I access the Arvinas presentation live?
A live audio webcast of the Arvinas presentation will be available on their website under “Events and Presentations.”
What is VEPPANU and its significance?
VEPPANU is the first FDA-approved PROTAC for treating ER+/HER2- advanced breast cancer, developed by Arvinas and Pfizer.
What clinical programs is Arvinas currently pursuing?
Arvinas is advancing multiple investigational drugs targeting diseases such as neurodegenerative disorders and various types of cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- JOHN G HOUSTON has made 0 purchases and 3 sales selling 35,297 shares for an estimated $466,153.
- BRIGGS MORRISON purchased 20,000 shares for an estimated $268,070
- NOAH BERKOWITZ (Chief Medical Officer) has made 0 purchases and 3 sales selling 23,228 shares for an estimated $249,410.
- RANDY TEEL (President and CEO) has made 0 purchases and 5 sales selling 21,055 shares for an estimated $226,476.
- ANGELA M CACACE (Chief Scientific Officer) has made 0 purchases and 4 sales selling 17,858 shares for an estimated $194,449.
- ANDREW SAIK (Chief Financial Officer) has made 0 purchases and 2 sales selling 16,273 shares for an estimated $171,735.
- DAVID K LOOMIS (VP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 4,043 shares for an estimated $44,623.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ARVN Hedge Fund Activity
We have seen 93 institutional investors add shares of $ARVN stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOGOS GLOBAL MANAGEMENT LP removed 5,575,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $66,119,500
- POINT72 ASSET MANAGEMENT, L.P. removed 2,085,554 shares (-90.1%) from their portfolio in Q1 2026, for an estimated $22,106,872
- VANGUARD GROUP INC removed 1,331,629 shares (-15.6%) from their portfolio in Q4 2025, for an estimated $15,793,119
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,189,227 shares (+471.4%) to their portfolio in Q1 2026, for an estimated $12,605,806
- OPALEYE MANAGEMENT INC. removed 987,818 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,715,521
- VESTAL POINT CAPITAL, LP added 905,465 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,597,929
- TWO SIGMA INVESTMENTS, LP added 839,651 shares (+84.6%) to their portfolio in Q1 2026, for an estimated $8,900,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 6 analysts offer price targets for $ARVN in the last 6 months, with a median target of $19.5.
Here are some recent targets:
- Jeet Mukherjee from BTIG set a target price of $18.0 on 05/13/2026
- Etzer Darout from Barclays set a target price of $20.0 on 05/13/2026
- Yigal Nochomovitz from Citigroup set a target price of $24.0 on 05/04/2026
- Jonathan Miller from Evercore ISI Group set a target price of $19.0 on 02/25/2026
- Robert Driscoll from Wedbush set a target price of $11.0 on 02/25/2026
- Edward Tenthoff from Piper Sandler set a target price of $20.0 on 02/25/2026
Full Release
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
A live audio webcast of the presentation will be available here and under “ Events and Presentations ” on the Investors and Media section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer Inc., developed the first-and-only U.S. Food and Drug Administration (FDA) approved PROTAC, a type of heterobifunctional protein degrader, VEPPANU
™
(vepdegestrant), for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Arvinas and Pfizer have entered into a transaction with Rigel Pharmaceuticals, Inc. for the exclusive global rights of VEPPANU; closing of the transaction is subject to the parties’ receipt of any necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for the treatment of Spinal-Bulbar Muscular Atrophy, also known as Kennedy’s disease; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X .
VEPPANU is a trademark of Arvinas Operations, Inc.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Alyssa Kuciunas
+1 (331) 481-3751
[email protected]
